TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Recruiting · NCT04701476 · Registry updated 2026-04-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-04-16 | NCT04701476 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Teclison Ltd. | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| China Medical University Hsinchu Hospital | Hsinchu | Taiwan | 1 |
| Chung Shan Medical University Hospital | Taichung | Taiwan | 10 |
| University of California, Irvine Medical Center | Orange | United States | 13 |